Vitamin D and breast cancer

Oncologist

Volumn 17, Issue 1, 2012, Pages 36-45

  Shao, Theresa ^a,c   Klein, Paula ^a,c   Grossbarda, Michael L ^a,b,c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c Institute for Head and Neck and Thyroid Cancer   (United States)

Author keywords

25 hydroxyvitamin D; Breast cancer; Chemoprevention; Sunlight; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; COLECALCIFEROL; ESTROGEN; PLACEBO; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR;

APOPTOSIS; BREAST CANCER; CANCER INVASION; CANCER RISK; DNA POLYMORPHISM; DRUG MEGADOSE; GROWTH DISORDER; HUMAN; HYPERCALCEMIA; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUN EXPOSURE; VITAMIN D METABOLISM; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; VITAMIN D;

EID: 84856246076     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0278     Document Type: Review

References (104)

1. Garland FC, Garland CF, Gorham ED et al. Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation. Prev Med 1990;19:614-622.
2. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
3. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-895.
4. Carlberg C. Current understanding of the function of the nuclear vitaminDreceptor in response to its natural and synthetic ligands. Recent Results Cancer Res 2003;164:29-42.
5. Haddad JG Jr, Rojanasathit S. Acute administration of 25-hydroxycholecalciferol in man. J Clin Endocrinol Metab 1976;42:284-290.
6. Looker AC, Pfeiffer CM, Lacher DA et al. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am J Clin Nutr 2008;88:1519-1527.
7. Wortsman J, Matsuoka LY, Chen TC et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690-693.
8. Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86:888-894.
9. Welsh J. Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res 2007; 22(suppl 2):V86-V90.
10. Townsend K, Evans KN, Campbell MJ et al. Biological actions of extra-renal 25-hydroxyvitamin D-1α-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol 2005;97:103-109.
11. Jensen SS, Madsen MW, Lukas J et al. Inhibitory effects of 1α,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 2001;15:1370-1380.
12. Simboli-Campbell M, Narvaez CJ, van Weelden K et al. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 1997;42:31-41.
13. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002;9:45-59.
14. James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996;58:395-401.
15. Ooi LL, Zhou H, Kalak R et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res 2010; 70:1835-1844.
16. Wang Q, Lee D, Sysounthone V et al. 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function-and cell-specific additive effects. Breast Cancer Res Treat 2001;67:157-168.
17. Koli K, Keski-Oja J. 1α,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasionassociated proteases in cultured malignant cells. Cell Growth Differ 2000;11:221-229.
18. Krishnan AV, Swami S, Peng L et al. Tissueselective regulation of aromatase expression by calcitriol: Implications for breast cancer therapy. Endocrinology 2010;151:32-42.
19. James SY, Mackay AG, Binderup L et al. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells J Endocrinol 1994;141: 555-563.
20. Stoica A, Saceda M, Fakhro A et al. Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem 1999;75:640-651.
21. Tangpricha V, Spina C, Yao M et al. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr 2005;135: 2350-2354.
22. Welsh J. Vitamin D and breast cancer: Insights from animal models. Am J Clin Nutr 2004; 80(6 suppl):1721S-1724S.
23. Narvaez CJ, Zinser G, Welsh J. Functions of 1α,25-dihydroxyvitamin D(3) in mammary gland: From normal development to breast cancer. Steroids 2001;66:301-308.
24. Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 2006;25:621-633.
25. Wang D, Dubois RN. Cyclooxygenase-2: A potential target in breast cancer. Semin Oncol 2004; 31(suppl 3):64-73.
26. Ristimäki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62: 632-635.
27. Boscoe FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 2006;6: 264.
28. Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002;94:272-281.
29. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990;19:820-824.
30. Porojnicu A, Robsahm TE, Berg JP et al. Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: A possible role of sun-induced Vitamin D. J Steroid Biochem Mol Biol 2007;103:675-678.
31. Porojnicu AC, Lagunova Z, Robsahm TE et al. Changes in risk of death from breast cancer with season and latitude: Sun exposure and breast cancer survival in Norway. Breast Cancer Res Treat 2007; 102:323-328.
32. Robsahm TE, Tretli S, Dahlback A et al. Vitamin D3 from sunlight may improve the prognosis of breast-, colon-and prostate cancer (Norway). Cancer Causes Control 2004;15:149-158.
33. John EM, Schwartz GG, Dreon DM et al. Vitamin D and breast cancer risk: The NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 1999;8:399-406.
34. Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer 2007;59:54-61.
35. Knight JA, Lesosky M, Barnett H et al. Vitamin D and reduced risk of breast cancer: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:422-429.
36. Levi F, Pasche C, Lucchini F et al. Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer 2001;91:260-263.
37. Potischman N, Swanson CA, Coates RJ et al. Intake of food groups and associated micronutrients in relation to risk of early-stage breast cancer. Int J Cancer 1999;82:315-321.
38. Rossi M, McLaughlin JK, Lagiou P et al. Vitamin D intake and breast cancer risk: A case-control study in Italy. Ann Oncol 2009;20:374-378.
39. Simard A, Vobecky J, Vobecky JS. VitaminD deficiency and cancer of the breast: An unprovocative ecological hypothesis. Can J Public Health 1991;82:300-303.
40. Decarli A, Franceschi S, Ferraroni M et al. Validation of a food-frequency questionnaire to assess dietary intakes in cancer studies in Italy. Results for specific nutrients. Ann Epidemiol 1996;6: 110-118.
41. Frazier AL, Li L, Cho E et al. Adolescent diet and risk of breast cancer. Cancer Causes Control 2004;15:73-82.
42. Lin J, Manson JE, Lee IM et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 2007;167:1050-1059.
43. McCullough ML, Rodriguez C, Diver WR et al. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2898-2904.
44. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: The Iowa Women's Health Study. Cancer Causes Control 2007;18:775-782.
45. Shin MH, Holmes MD, Hankinson SE et al. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 2002; 94:1301-1311.
46. Xie SP, Pirianov G, Colston KW. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer 1999; 35:1717-1723.
47. Colston KW, Perks CM, Xie SP et al. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 1998;20:157-162.
48. Xie SP, James SY, Colston KW. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol 1997;154:495-504.
49. Bezemer ID, Rinaldi S, Dossus L et al. C-peptide, IGF-I, sex-steroid hormones and adiposity: A cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2005; 16:561-572.
50. Abbas S, Linseisen J, Slanger T et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008;29:93-99.
51. Abbas S, Chang-Claude J, Linseisen J. Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer 2009;124:250-255.
52. Bertone-Johnson ER. Prospective studies of dietary vitamin D and breast cancer: More questions raised than answered. Nutr Rev 2007;65:459-466.
53. Chlebowski RT, Johnson KC, Kooperberg C et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008; 100:1581-1591.
54. Crew KD, Gammon MD, Steck SE et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2009;2:598-604.
55. Engel P, Fagherazzi G, Boutten A et al. Serum 25(OH) vitamin D and risk of breast cancer: A nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 2010;19: 2341-2350.
56. Freedman DM, Chang SC, Falk RT et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2008;17:889-894.
57. Lowe LC, Guy M, Mansi JL et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005;41: 1164-1169.
58. Chen P, Hu P, Xie D et al. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 2010;121:469-477.
59. Gammon MD, Neugut AI, Santella RM et al. The Long Island Breast Cancer Study Project: Description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat 2002;74:235-254.
60. Lukanova A, Lundin E, Zeleniuch-Jacquotte A et al. Body mass index, circulating levels of sexsteroid hormones, IGF-I and IGF-binding protein-3: A cross-sectional study in healthy women. Eur J Endocrinol 2004;150:161-171.
61. Freedman DM, Looker AC, Chang SC et al. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007;99:1594-1602.
62. Goodwin PJ, Ennis M, Pritchard KI et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009;27:3757-3763.
63. Gerend MA, Pai M. Social determinants of Black-White disparities in breast cancer mortality: A review. Cancer Epidemiol Biomarkers Prev 2008;17:2913-2923.
64. Albain KS, Unger JM, Crowley JJ et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009;101:984-992.
65. Zadshir A, Tareen N, Pan D et al. The prevalence of hypovitaminosis D among US adults: Data from the NHANES III. Ethn Dis 2005;15(suppl 5): S5-97-S5-101.
66. Steck SE, Rosling R, Murphy EA et al. Vitamin D status and breast cancer aggressiveness among African women in South Carolina. Presented at the American Association for Cancer Research Conference, Miami, FL, September 30 to October 3, 2010.
67. Guy M, Lowe LC, Bretherton-Watt D et al. VitaminDreceptor gene polymorphisms and breast cancer risk. Clin Cancer Res 2004;10:5472-5481.
68. Chen WY, Bertone-Johnson ER, Hunter DJ et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:2335-2339.
69. Uitterlinden AG, Fang Y, van Meurs JB et al. VitaminDreceptor gene polymorphisms in relation to Vitamin D related disease states. J Steroid Biochem Mol Biol 2004;89-90:187-193.
70. Buyru N, Tezol A, Yosunkaya-Fenerci E et al. Vitamin D receptor gene polymorphisms in breast cancer. Exp Mol Med 2003;35:550-555.
71. Bretherton-Watt D, Given-Wilson R, Mansi JL et al. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer 2001;85:171-175.
72. Hou MF, Tien YC, Lin GT et al. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat 2002;74:1-7.
73. Ingles SA, Garcia DG, WangWet al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000;11: 25-30.
74. Wang TJ, Zhang F, Richards JB et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 2010;376:180-188.
75. Abbas S, Linseisen J, Slanger T et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 2008;17:1339-1343.
76. McCullough ML, Stevens VL, Diver WR et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: A nested case-control study. Breast Cancer Res 2007;9:R9.
77. Prentice RL, Anderson GL. The women's health initiative: Lessons learned. Annu Rev Public Health 2008;29:131-150.
78. Lappe JM, Travers-Gustafson D, Davies KM et al. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591.
79. Refice SF, Hershman DL, Maurer MA et al. Safety of high-dose vitamin D supplementation in premenopausal women at high risk for breast cancer. Presented at the 33rd San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010.
80. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr 2008;87:1087S-1091S.
81. Holick MF, Siris ES, Binkley N et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215-3224.
82. Lips P, Chapuy MC, Dawson-Hughes B et al. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999;9:394-397.
83. Holick MF. 25-OH-vitamin D assays. J Clin Endocrinol Metab 2005;90:3128-3129.
84. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003;921:1-164, back cover.
85. Dawson-Hughes B, Mithal A, Bonjour JP et al. IOF position statement: Vitamin D recommendations for older adults. Osteoporos Int 2010;21: 1151-1154.
86. Ross AC, Manson JE, Abrams SA et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 2011;96:53-58.
87. Tangpricha V, Pearce EN, Chen TC et al. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002;112:659-662.
88. Gordon CM, DePeter KC, Feldman HA et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004;158: 531-537.
89. Sullivan SS, Rosen CJ, Halteman WA et al. Adolescent girls in Maine are at risk for vitamin D insufficiency. J AmDiet Assoc 2005;105:971-974.
90. Khan QJ, Reddy PS, Kimler BF et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010;119:111-118.
91. Friedman CF, DeMichele A, Su HI et al. Vitamin D deficiency in post-menopausal breast cancer survivors. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010.
92. Heaney RP, Dowell MS, Hale CA et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142-146.
93. Garland CF, Gorham ED, Mohr SB et al. Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol 2007;103:708-711.
94. Caniggia A, Lorè F, di CairanoGet al. Main endocrine modulators of vitamin D hydroxylases in human pathophysiology. J Steroid Biochem 1987;27: 815-824.
95. Gilad LA, Bresler T, Gnainsky J et al. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol 2005;185:577-592.
96. Holick MF, Biancuzzo RM, Chen TC et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008;93:677-681.
97. Heaney RP, Davies KM, Chen TC et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003;77:204-210.
98. Holick MF, Chen TC. Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr 2008;87:1080S-1086S.
99. Chel V, Wijnhoven HA, Smit JH et al. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int 2008;19:663-671.
100. Ish-Shalom S, Segal E, Salganik T et al. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 2008;93:3430-3435.
101. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998;351: 805-806.
102. Crew KD, Shane E, Cremers S et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009;27:2151-2156.
103. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88:582S-586S.
104. Hathcock JN, Shao A, Vieth R et al. Risk assessment for vitamin D. Am J Clin Nutr 2007;85: 6-18.